Table 5.
Unadjusted and adjusted relative hazards of death (all-cause mortality)
|
Unadjusted analysis |
Adjusted analysis* |
Adjusted analysis† |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Overall comparison (two-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Tocilizumab (any) | 0·28 (0·15–0·50) | <0·0001 | 0·36 (0·20–0·66) | 0·0009 | 0·38 (0·17–0·83) | 0·015 |
| Baseline PaO2/FiO2≤150 mmHg (two-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Tocilizumab (any)‡ | 0·11 (0·04–0·27) | .. | 0·09 (0·03–0·24) | .. | 0·03 (0·00–0·24) | .. |
| Interaction p value‡ | .. | .. | .. | .. | .. | 0·12 |
| Baseline PaO2/FiO2>150 mmHg (two-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Tocilizumab (any)‡ | 0·22 (0·08–0·63) | .. | 0·39 (0·12–1·20) | .. | 0·44 (0·11–1·73) | .. |
| Overall comparison (three-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Subcutaneous tocilizumab subcutaneous | 0·30 (0·14–0·66) | 0·0025 | 0·37 (0·17–0·83) | 0·016 | 0·44 (0·17–1·14) | 0·091 |
| Intravenous tocilizumab | 0·25 (0·11–0·58) | 0·0012 | 0·35 (0·15–0·80) | 0·013 | 0·29 (0·09–0·99) | 0·048 |
Data are n (95% CI) unless otherwise indicated. Data obtained using a Cox regression model. 152 patients with missing PaO2/FiO2 were not included in the stratified analysis. PaO2/FiO2=ratio of arterial oxygen partial pressure to fractional inspired oxygen.
*
Adjusted for age, sex, and recruiting centre.
†
Adjusted for age, sex, recruiting centre, duration of symptoms, and Subsequent Organ Failure Assessment (SOFA) score.
‡
Some p values intentionally left out as p values in the subsets are not interpretable.